Ru between 2005 and 2010. Medical records were retrospectively reviewed. We compared post-treatment visual acuity (VA), toxicity, and oncologic outcomes. 103 Pd patients (n = 124) and 106 Ru patients (n = 42) had a median follow-up of 4.2 and 5.0 years, respectively. Radiation retinopathy-free survival was similar for both radioisotopes, but 106 Ru had lower grades of retinopathy (P = 0.006). 103 Pd was associated with worse VA preservation (≥20/40) by year 3 (odds ratio: 3.8; 95% confidence interval: 1.01-14.31, P = 0.048). 103 Pd was associated with higher distant metastases-free survival (DMFS) in multivariate analysis (hazard ratio: 0.10; 95% confidence interval: 0.02-0.38; P < 0.001). 106 Ru had lower grades of radiation retinopathy and improved long-term VA preservation, but also inferior 106 Ru showed lower grades of radiation retinopathy and improved 3-year visual acuity (VA) preservation -but also lower distant metastasis-free survival -compared with 103 Pd.
Ocular melanoma is the most common primary intraocular tumor in adults and the second most common type of melanoma after cutaneous, accounting for 3.7% of all cases. It arises from melanocytes, usually in the uvea (82.5%), or less frequently in the conjunctiva. Within the uveal tract, 86.3% occur in the choroid; iris and ciliary body melanoma are much less common. The incidence of choroid melanoma in the USA is ∼ 4.3 cases per million persons; melanoma of the iris and ciliary body contributes another 0.7 cases per million persons. Patients are typically diagnosed between the ages of 50 and 80 years, with peak incidence in the seventh decade [1] .
Plaque radiation therapy (RT), with proper tumor selection, leads to local control and survival outcomes similar to those achieved by enucleation, as reported in the Collaborative Ocular Melanoma Study (COMS). In this trial, which enrolled from 1986 to 2003, patients with medium-sized tumors were randomized to enucleation versus iodine-125 ( 125 I) plaque brachytherapy. Longterm analysis showed no difference in overall survival or distant metastases [2] [3] [4] . However, although 70% of patients had baseline VA 20/40 or better, only 34% of patients showed 20/40 vision or better at 3 years [5] . Some of the factors that influence post-treatment VA include tumor characteristics (mainly size and distance from the fovea), age, and ocular comorbidities such as diabetes. Secondary effects of radiation on normal ocular structures -namely radiation retinopathy (ischemic, exudative, hemorrhagic, or atrophic), radiation choroidopathy, radiation optic neuropathy, and radiation-induced cataract -are also implicated as contributors to loss in VA [6] .
The most commonly used radioisotopes for ocular melanoma brachytherapy are 106 Ru, 103 Pd, and 125 I (please see Table 1 for a summary of the characteristics of these radioisotopes). Because of the relatively gradual dose fall-off, 125 I delivers a higher dose to critical eye structures including the macula, lens, and optic discs. Finger et al. [7] [8] [9] report that compared with 125 I, 103 Pd offers an opportunity for radiation sparing of ocular structures while maintaining better VA and equivalent rates of local control. 103 Pd, because of its lower energy resulting in steeper isodose fall-off, has been shown to decrease dose to the macula and optic nerve relative to the 125 I [9] . We recently reported an analysis of patients treated with plaque brachytherapy at Emory with either 103 Pd versus 125 I, which showed that 103 Pd is associated independently with superior long-term VA preservation and lower incidence of radiation retinopathy compared with 125 I [10] . 106 Ru, a β emitter rather than a γ emitter, has an even sharper dose fall-off than even 103 Pd. Dosimetric comparison of 106 Ru and 125 I for tumors less than or equal to 5 mm shows translation of this sharp dose fall-off to a clinically relevant reduction in radiation dose to normal eye structures [11] . In addition, a recent retrospective report from MD Anderson showed equivalent overall survival, improved enucleation-free survival (EFS), and reduced radiation retinopathy in patients receiving 106 Ru compared with patients receiving 125 I plaque brachytherapy [12] . Ru as the sharp dose fall-off of this isotope would necessitate a high dose to the sclera to achieve a proper dose distribution to the tumor in the choroid and such a dose to the sclera could result in scleral necrosis. We excluded patients with incomplete demographic data, pretreatment VA data, RT treatment data, tumor located in the iris or ciliary body, and metastatic disease at initial presentation. We also excluded patients who had undergone transpupillary thermotherapy.
Patients were treated at both institutions with a prescribed RT dose of 85 Gy as per the COMS trial [13] . We have previously published the detailed treatment protocols for Emory University and Cleveland Clinic [10, 14] . Briefly, plaque size was chosen on the basis of tumor size, allowing for a 2 mm margin around the circumference of the tumor. For tumors more than 5 mm in height, RT dose was prescribed to a height of 5 mm.
Medical record review
Baseline patient data included age at the time of treatment, sex, presence or absence of diabetes mellitus, bestcorrected VA before treatment, and tumor characteristics including laterality, location (o'clock), largest radial dimension, area, and height. Treatment data included date of plaque placement, radioisotope ( 106 Ru or 103 Pd), plaque size, RT dose, and distance of the tumor to the optic nerve (measured from the edge of the tumor to the center of the disc) and macula (measured from the edge of the tumor to the fovea). We also determined the grade of radiation retinopathy, if any, per the Finger classification [15] . Follow-up data included length of follow-up, VA at annual follow-up visits, date of diagnosis of complications of radiotherapy (e.g. radiation retinopathy), development of distant metastases, secondary enucleation, and date of death from all causes of mortality. Baseline and follow-up VA measurements were recorded using a Snellen VA scale. Count fingers VA was converted into a Snellen VA recording value [16] . Hand motion only and light perception only vision were recorded as a decimal acuity of 0.005, and no light perception and enucleation were assigned a decimal acuity of one line worse than the lowest decimal VA (0.0015) [17] .
Statistical analysis
We analyzed three VA measures to determine the toxicity of the radioisotopes: visual preservation, loss, and change. Survival was defined as time from the date of plaque placement to one of the following: death [overall survival (OS)], distant metastases-free survival (DMFS), EFS, radiation retinopathy free survival (RRFS), censored at last follow-up. Survival was estimated using the Kaplan-Meier method, and survival distributions were compared using log-rank tests. Firth's penalized maximum likelihood estimation was implemented for the DMFS and EFS models to reduce bias in the parameter estimates and confidence intervals because of the small number of events in each model. Treatment groups and vision endpoints were compared across categorical endpoints using χ 2 -tests or Fisher's exact tests, where appropriate, and across continuous variables using analysis of variance. Multivariable analysis (MVA) for time-to-event endpoints was carried out using Cox proportional hazards modeling and included the following factors for OS, DMFS, and EFS: age at the time of the procedure, tumor area, tumor height, radioisotope. MVA for RRFS and VA endpoints (loss, preservation and change at 1, 2, and 3 years) included:radioisotope, pretreatment vision, distance from the macula to the tumor, distance from the optic disk to the tumor, tumor area, tumor height, and age at the time of the procedure. MVA for VA endpoints at each time point was carried out using logistic regression modeling.
All analyses were carried out using the SAS 9.3 version statistical software package (SAS Institute, Cary, North Carolina, USA). All statistical analyses were two-sided, and P values less than 0.05 were considered statistically significant.
Results
At Emory University, 124 patients were treated with Table 2 summarizes the patient, disease, and treatment characteristics of each cohort. There were no significant differences in the cohorts except for a minor difference in prescribed dose, and also difference in radiation retinopathy grade per the Finger classification [15] . 106 Ru patients had lower grades of retinopathy compared with the 103 Pd cohort at the latest follow-up visit (P = 0.006). At baseline, 106 Ru and 103 Pd patients had similar distributions of pretreatment VA.
EFS could not be analyzed as there were too few events in the cohorts: two in the 106 Ru cohort and one in the 103 Pd cohort. Five-year DMFS was higher in the 103 Pd cohort: 96.5 versus 78.6% in the 106 Ru cohort (P = 0.0002) (Fig. 1) retinopathy. Three-year RRFS was not statistically different between 103 Pd and 106 Ru (65.2 vs. 50.6%, respectively, P = 0.5420) (Fig. 2) . Table 3 summarizes the rates of VA loss, preservation, and stability/improvement over 3 years for 106 Ru and 103 Pd.
The significantly higher DMFS for 103 Pd persisted in MVA [hazard ratio (HR): 0.10; 95% confidence interval (CI): 0.02-0.38; P < 0.001]. Tumor height was associated significantly with worse DMFS in MVA (HR: 3.07; 95% CI: 1.60-5.90; P < 0.001); no other covariates were associated significantly with DMFS. The higher OS found for 103 Pd also persisted on MVA (HR: 0.19; 95% CI: 0.07-0.54; P = 0.002). Increasing tumor height (HR: 2.43; 95% CI: 1.38-4.27; P = 0.002) and older age at the time of procedure (HR: 1.15; 95% CI: 1.07-1.23; P < 0.001) were associated significantly with lower OS on MVA; other covariates were not associated significantly with OS. In MVA of rates of RRFS, increasing distance from the optic disc to the tumor was shown to have significantly higher RRFS (HR: 0.83; 95% CI: 0.74-0.93; P < 0.001); no other covariates (including radioisotope used) were found to be associated significantly with RRFS in MVA. In MVA for VA preservation (post-treatment vision 20/40 or better), the 103 Pd radioisotope was associated with worse outcomes (odds ratio: 3.8; 95% CI: 1.01-14.31; P = 0.048); no other covariates had significant associations with VA preservation. In MVA for VA loss (impairment in vision to 20/200 or worse), increasing distance from the optic disk to the tumor was associated with improved outcomes (odds ratio: 0.78; 95% CI: 0.63-0.97; P = 0.023); no other covariates had significant associations with VA loss. No covariates (including radioisotope used) were associated significantly with VA stability/improvement in MVA.
Discussion
Since the initiation of the COMS study in 1986, there has been a sharp and steady increase in the use of radiation and decline in surgery for uveal melanoma. [18] . This paradigm shift has likely improved patient quality of life through ocular preservation, while maintaining DMFS and OS. In the present analysis, we sought to compare, for the first time, the oncologic, toxicity, and VA outcomes of 106 Ru and 103 Pd episcleral plaque brachytherapy in the definitive treatment of choroidal melanoma with apical height up to 5 mm. In this multiinstitutional analysis, we found that the 103 Pd group had improved DMFS at 5 years (96.5 vs. 78.6%, P = 0.0002). Three-year RRFS was equivalent in both cohorts, but 106 Ru had lower grades of retinopathy. 3-year VA preservation was worse in the 103 Pd cohort in MVA. We report improved OS with 103 Pd; however, we believe that this significant difference is confounded by the competing comorbidities and selection bias inherent to a retrospective analysis of all-cause mortality.
Although a small number of patients (4%) present with distant metastases at diagnosis, about half of the patients develop metastases in their disease course [19] , which is significant because the prognosis of metastatic disease has been historically very poor. At 5 and 10 years of follow-up, choroidal melanoma metastases have been reported in 15 and 25% of patients, respectively [20] . Uveal melanoma has a high propensity for the liver (94%), followed by lung (24%) and bone (16%) [21] . Memorial Sloan Kettering reviewed their experience with 106 Ru for definitive management of uveal melanoma and found a 5-year DMFS of 88.6% [22] . Their cohort had a median tumor diameter of 9.4 mm and height of 2.6 mm, which is similar to Cleveland Clinic's cohort, which had median values for tumor diameter of 9.75 mm and height of 2.5 mm. Finger et al. [7] reported 5-year DMFS of 92.7% for their 103 Pd cohort consisting of mainly medium-sized choroidal melanoma, which is similar to our Emory experience. Because of the inherent limitations of a retrospective analysis, the significance of the inferior DMFS found for 106 Ru in our study remains unclear, although the suggestion of a slight inferiority in terms of DMFS for 106 Ru is consistent with the other limited literature.
Multiple reports from throughout the world have detailed the VA and toxicity outcomes of 106 Ru, although it is somewhat difficult to compare these studies directly as each report contains unique baseline patient and tumor characteristics. In our Ru. In their patients, the median tumor height was 4.3 mm, the median diameter was 10 mm, the median distance from the macula was 2.0 mm, and the median distance from the optic disc was 3 mm. These tumors were thicker and closer to the macula and optic disc than in our 106Ru cohort. The reported 5-year VA 20/40 or better was 31% and VA 20/200 or better was 49% [24] . A report of 458 patients in the UK with choroidal melanoma (median tumor height 3.2 mm and median diameter Radiation retinopathy-free survival for ruthenium-106 versus palladium-103. Ru patients have radiation retinopathy (median tumor height 3.05 mm and median diameter 9.6 mm) at median 67 months of follow-up [12] . At Helsinki University, 28% of 106 Ru patients (median tumor height 1.9 mm and median diameter 7 mm) experienced radiation maculopathy at 5 years [25] .
As with any retrospective study, there are several limitations in the present analysis. There is potential for selection bias because of the nonrandomized treatment cohorts. However, both Emory University and Cleveland Clinic have uniform follow-up patterns, and most patients have detailed clinical records that have been maintained meticulously. Patient, tumor, and treatment characteristics were well documented at both institutions, and were well balanced between institutional cohorts. The quality of documentations made it possible to report grade of radiation retinopathy, a variable that is not found frequently in the literature. Once again, there may be confounding because of differences in surgeon experience between Emory University and Cleveland Clinic. Finally, we have relatively small cohorts, especially for 106 Ru brachytherapy, which is attributable to the limited availability of 106 Ru in the USA during the last few decades.
Conclusion
We compared oncologic, toxicity, VA acuity outcomes of patients treated with episcleral plaque brachytherapy for choroidal melanoma up to 5 mm in height, and found that 106 Ru yielded similar rates, but lower grades of radiation retinopathy, and superior VA preservation at 3 years, compared with 103 Pd. This advantage for 106 Ru in terms of toxicity is perhaps compromised by lower DMFS compared to 103 Pd; though a mechanism for a DMFS advantage for 103 Pd remains unclear and most likely this finding is due to imbalances between patient groups. At present, both radioisotopes remain appropriate for this population, and it seems that a clear answer in terms of the superiority of one over the other will not be possible without prospective studies.
